Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2006-01-03
2006-01-03
Kemmerer, Elizabeth (Department: 1647)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C424S009200, C800S013000, C800S014000, C800S018000
Reexamination Certificate
active
06982361
ABSTRACT:
Methods and compositions for use in treating anxiety are provided. In the subject methods, an effective amount of an agent having ApoE3 activity is administered to a host suffering from an anxiety, e.g. excessive anxiety, unwanted anxiety, an anxiety disorder, etc. Also provided are methods and compositions for modulating adrenal steroidogenesis and/or release, particularly stress induced adrenal steroidogenesis and/or release, and the hippocampal-pituitary-adrenal (HPA) axis. In these methods, an effective amount of an ApoE activity modulating agent, e.g. an ApoE agonist or antagonist, is administered to the host.
REFERENCES:
patent: 5145866 (1992-09-01), Dunn et al.
patent: 5767337 (1998-06-01), Roses et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5882671 (1999-03-01), Helton et al.
patent: 6046381 (2000-04-01), Mucke et al.
Roses, AD. Apolipoprotein E in neurology. Curr Opin Neurol 9: 265-270, 1996.
Polvikoski et al. Apolipoprotein E, dementia, and cortical depression of beta-amyloid protein. N Engl J Med 333: 1242-1247, 1995.
File et al. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Research 805: 234-240, 1998.
Orrell et al. Psychosocial stress and anxiety in senile dementia. J. Affective Disorders 39: 165-173, 1996.
Cacabelos et al. APOE related frequency of cognitive and noncognitive symtoms in dementia. Meth Find Exp Clin Pharmacol 18(10): 693-706, 1996.
Roses et al. ApoE, Alzheimer's disease, and recovery from brain stress. Annals NY Acad Sci 826: 200-212, 1997.
Veinbergs et al. Differential neurotrophic effects of apolipoprotein E in aged transgenic mice. Neuroscience Letters 265: 218-222, 1999.
Masliah et al. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Research 751: 307-314, 1997.
Raber et al. Differential effects of human apolipoprotein E isoforms on spatial learning/memory revealed in ApoE knockout mice. Society for Neurosci Abs 24(1-2): 736, 1998.
Wozniak et al. ApoE4 transgenic male mice are profoundly impaired on the working memory protocol of the radial arm maze. Society for NeuroSci Abs 25(1-2): 55, 1999.
Moechars et al. Expression in brain of amyloid precursor protein mutated in the alpha secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15(6): 1265-1274, 1996.
Stevenson et al. Phenotypic correction of hypercholesterolemia in ApoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol 15: 479-484, 1995.
Chemerinski et al. Prevalence and correlates of anxiety in Alzheimer's disease. Depression and Anxiety 7: 166-170, 1998.
Crawley, JN. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motors abilities, and specific behavioral tests. Brain Research 835: 18-26, 1999.
Buttini et al. Expression of human Apolipoprotein E3 or E4 in the brains of ApoE-/- mice: isoform-specific effects on neurodegeneration. J. Neuroscience 19(12): 4867-4880, 1990.
Pellow et al. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem Behavior 24: 525-529, 1986.
Raber, et al., “Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females”, Proc. Natl. Acad. Sci USA., vol. 95, pp. 10914-10919, Sep. 1998.
Mucke Lennart
Raber Jacob
Borden Paula A.
Bozicevic Field & Francis LLP
Bunner Bridget E.
Field Bret E.
Kemmerer Elizabeth
LandOfFree
Method of screening a compound for anxiolytic activity in an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening a compound for anxiolytic activity in an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening a compound for anxiolytic activity in an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3579012